Cargando…

A patient-reported outcome measure for patients with pituitary adenoma undergoing transsphenoidal surgery

PURPOSE: Pituitary adenomas affect patients’ quality-of-life (QoL) across several domains, with long-term implications even following gross-total resection or disease remission. While clinical outcomes can assess treatment efficacy, they do not capture variations in QoL. We present the development a...

Descripción completa

Detalles Bibliográficos
Autores principales: Karvandi, Elika, Hanrahan, John Gerrard, Khan, Danyal Zaman, Boloux, Pierre-Marc, Bremner, Fion, Cabrilo, Ivan, Dorward, Neil, Grieve, Joan, Jackson, Sue, Jimenez, Glenda, Serrano, Inma, Nowak, Victoria Anne, Kolias, Angelos, Baldeweg, Stephanie E., Marcus, Hani Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345822/
https://www.ncbi.nlm.nih.gov/pubmed/35838913
http://dx.doi.org/10.1007/s11102-022-01251-x
Descripción
Sumario:PURPOSE: Pituitary adenomas affect patients’ quality-of-life (QoL) across several domains, with long-term implications even following gross-total resection or disease remission. While clinical outcomes can assess treatment efficacy, they do not capture variations in QoL. We present the development and validation of a patient reported outcome measure (PROM) for patients with pituitary adenomas undergoing transsphenoidal surgery. METHODS: The COSMIN checklist informed the development of the pituitary outcome score (POS). Consecutive patients undergoing surgical treatment for suspected pituitary adenoma at a single centre were included prospectively. An expert focus group and patient interviews informed item generation. Item reduction was conducted through exploratory factor analysis and expert consensus, followed by assessment of the tool’s validity, reliability, responsiveness, and interpretability. RESULTS: 96 patients with a median age of 50 years validated the POS. The final questionnaire included 25 questions with four subscales: EQ-5D-5L-QoL, Visual Symptoms, Endocrine Symptoms and Nasal Symptoms. CONCLUSION: The POS is the first validated PROM for patients undergoing transsphenoidal surgery for a pituitary adenoma. This PROM could be integrated into contemporary practice to provide patient-centred outcomes assessment for this patient group, aligning more closely with patient objectives. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11102-022-01251-x.